The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The Latest on Vaccinations, Leprosy & Lyme Disease

The Latest on Vaccinations, Leprosy & Lyme Disease

March 19, 2019 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Hugh Sitton / OFFSET BY shutterstocK

Hugh Sitton / OFFSET BY shutterstocK

CHICAGO—Keith Winthrop, MD, MPH, professor of public health and preventive medicine at the Oregon Health & Science University School of Medicine, Portland, Ore., began the vaccination session at the 2018 ACR/ARHP Annual Meeting with a review of vaccination timing and targets. He presented a clinically relevant snapshot of the vaccines rheumatologists should consider and emphasized that, in general, vaccines are underutilized in the rheumatology population. He first discussed the inactivated annual influenza vaccine, which he recommended for all rheumatological patients.

You Might Also Like
  • Vaccinations for Immunocompromised Patients Are Shared Responsibility of Specialists, Primary Care Physicians
  • Tips on Vaccinating Patients with Rheumatic Diseases
  • Letters: Detecting Lyme Disease May Require Thorough Testing
Explore This Issue
March 2019
Also By This Author
  • New Insights into CD8+ T Cells & Lupus

Healthcare providers have a choice of a high-dose flu vaccine or adjuvanted flu vaccine. The high-dose flu vaccine is indicated for patients older than 65 years of age. Research has shown it provides 24% greater efficacy against flu than the standard vaccine.1 Unfortunately, patients with rheumatoid arthritis (RA) may not respond as well. Nevertheless, preliminary research suggests that seroprotection with the high-dose vaccine in patients with RA is superior to the alternatives, and the argument could be made that even younger people with RA should receive the high-dose flu vaccine.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Winthrop also addressed the common concerns that immunosuppressive agents may further limit the efficacy of the vaccines. He began by reassuring the audience that most disease-modifying anti-rheumatic drugs (DMARDs) do not affect the efficacy of influenza vaccination. That said, new research indicates people who stopped methotrexate for two weeks prior to vaccination experienced superior seroprotection. Moreover, few patients with RA flared when off methotrexate, which suggests stopping methotrexate might be a nice strategy to improve seroprotection.

Dr. Winthrop described the two pneumococcal polysaccharide vaccines on the market: PPSV23, which protects against 23 types of pneumococcal bacteria, and PCV13, a conjugate vaccine that protects against 13 types of pneumococcal bacteria.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A few studies have examined seroprotection in immunosuppressed patients. Patients on tofacitinib who received PCV13 experienced a multifold titer rise.2 The same was true for patients on baricitinib, who also experienced a robust rise in antibody titer, although not as high as those on tofacitinib.3 Dr. Winthrop explained that this difference in response may be because the patients on tofacitinib were younger and had psoriasis, whereas the patients in the baricitinib study had RA and were older. Dr. Winthrop also noted that patients in these studies were likely on methotrexate, which meant they responded even though they were immunosuppressed. Despite this, he does try to suspend methotrexate before vaccinating. Dr. Winthrop concluded his talk by stating the “best time to vaccinate is when the patient is in front of you and you are thinking about it.”

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports Tagged With: 2018 ACR/ARHP Annual Meeting, leprosy, Lyme Disease, vaccinationIssue: March 2019

You Might Also Like:
  • Vaccinations for Immunocompromised Patients Are Shared Responsibility of Specialists, Primary Care Physicians
  • Tips on Vaccinating Patients with Rheumatic Diseases
  • Letters: Detecting Lyme Disease May Require Thorough Testing
  • Lyme Arthritis Treatment Protocols Critical as Lyme Disease Spreads

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.